Mundipharma International Limited – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “Mundipharma International Limited - Product Pipeline Review - 2013” provides data on the Mundipharma International Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mundipharma International Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Mundipharma International Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Mundipharma International Limited - Product Pipeline Review - 2013” provides data on the Mundipharma International Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mundipharma International Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Mundipharma International Limited and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Mundipharma International Limited - Brief Mundipharma International Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mundipharma International Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mundipharma International Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mundipharma International Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Mundipharma International Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mundipharma International Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mundipharma International Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mundipharma International Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mundipharma International Limited and identify potential opportunities in those areas.
Mundipharma International Limited Snapshot
Mundipharma International Limited Overview
Key Information
Key Facts
Mundipharma International Limited – Research and Development Overview
Key Therapeutic Areas
Mundipharma International Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Mundipharma International Limited – Pipeline Products Glance
Mundipharma International Limited – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mundipharma International Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Mundipharma International Limited – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mundipharma International Limited – Drug Profiles
(fluticasone proprionate + formoterol fumarate)
Product Description
Mechanism of Action
R&D Progress
bendamustine hydrochloride
Product Description
Mechanism of Action
R&D Progress
forodesine hydrochloride
Product Description
Mechanism of Action
R&D Progress
morphine sulfate
Product Description
Mechanism of Action
R&D Progress
NL-101
Product Description
Mechanism of Action
R&D Progress
pralatrexate
Product Description
Mechanism of Action
R&D Progress
Mundipharma International Limited – Pipeline Products by Route of Administration
Mundipharma International Limited – Pipeline Products By Mechanism of Action
Mundipharma International Limited – Recent Pipeline Updates
Mundipharma International Limited - Dormant Projects
Mundipharma International Limited – Company Statement
Mundipharma International Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Mundipharma International Limited, Recent Developments
Mundipharma International Limited- Press Release
Feb 20, 2013: Mundipharma Reports Publication Of Phase III Data Of Bendamustine Plus Rituximab In Lancet
Dec 04, 2010: BioCryst Reports Encouraging Data From Phase II Forodesine Study In Chronic Lymphocytic Leukemia
Sep 15, 2010: BioCryst Announces Results From Two Forodesine Oncology Studies
Jul 01, 2010: Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII
Jan 15, 2010: Biocryst Pharmaceuticals Achieves Enrollment Target For Forodesine CTCL Pivotal Study
Financial Deals Landscape
Mundipharma International Limited, Deals Summary
Mundipharma International Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Mundipharma Enters Into Agreement With Purdue Pharma
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Licensing Agreements
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Asset Transactions
Sosei Group Reacquires Rights To AD923 From Mundipharma
Acquisition
Mundipharma International Acquires Clinical Designs From Abingworth Management
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Mundipharma International Limited, Key Information
Mundipharma International Limited, Key Facts
Mundipharma International Limited – Pipeline by Indication, 2013
Mundipharma International Limited – Pipeline by Stage of Development, 2013
Mundipharma International Limited – Monotherapy Products in Pipeline, 2013
Mundipharma International Limited – Combination Treatment Modalities in Pipeline, 2013
Mundipharma International Limited – Filed, 2013
Mundipharma International Limited – Phase III, 2013
Mundipharma International Limited – Phase II, 2013
Mundipharma International Limited – Pre-Clinical, 2013
Mundipharma International Limited – Pipeline By Route of Administration, 2013
Mundipharma International Limited – Pipeline Products By Mechanism of Action, 2013
Mundipharma International Limited – Recent Pipeline Updates, 2013
Mundipharma International Limited - Dormant Developmental Projects,2013
Mundipharma International Limited, Other Locations
Mundipharma International Limited, Subsidiaries
Mundipharma International Limited, Deals Summary
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Mundipharma Enters Into Agreement With Purdue Pharma
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Sosei Group Reacquires Rights To AD923 From Mundipharma
Mundipharma International Acquires Clinical Designs From Abingworth Management
LIST OF FIGURES
Mundipharma International Limited – Pipeline by Indication, 2013
Mundipharma International Limited – Pipeline by Stage of Development, 2013
Mundipharma International Limited – Monotherapy Products in Pipeline, 2013
Mundipharma International Limited – Combination Treatment Modalities in Pipeline, 2013
Mundipharma International Limited – Pipeline By Route of Administration, 2013
Mundipharma International Limited - Pipeline Products By Mechanism of Action, 2013
Mundipharma International Limited Overview
Key Information
Key Facts
Mundipharma International Limited – Research and Development Overview
Key Therapeutic Areas
Mundipharma International Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Mundipharma International Limited – Pipeline Products Glance
Mundipharma International Limited – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mundipharma International Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Mundipharma International Limited – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mundipharma International Limited – Drug Profiles
(fluticasone proprionate + formoterol fumarate)
Product Description
Mechanism of Action
R&D Progress
bendamustine hydrochloride
Product Description
Mechanism of Action
R&D Progress
forodesine hydrochloride
Product Description
Mechanism of Action
R&D Progress
morphine sulfate
Product Description
Mechanism of Action
R&D Progress
NL-101
Product Description
Mechanism of Action
R&D Progress
pralatrexate
Product Description
Mechanism of Action
R&D Progress
Mundipharma International Limited – Pipeline Products by Route of Administration
Mundipharma International Limited – Pipeline Products By Mechanism of Action
Mundipharma International Limited – Recent Pipeline Updates
Mundipharma International Limited - Dormant Projects
Mundipharma International Limited – Company Statement
Mundipharma International Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Mundipharma International Limited, Recent Developments
Mundipharma International Limited- Press Release
Feb 20, 2013: Mundipharma Reports Publication Of Phase III Data Of Bendamustine Plus Rituximab In Lancet
Dec 04, 2010: BioCryst Reports Encouraging Data From Phase II Forodesine Study In Chronic Lymphocytic Leukemia
Sep 15, 2010: BioCryst Announces Results From Two Forodesine Oncology Studies
Jul 01, 2010: Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII
Jan 15, 2010: Biocryst Pharmaceuticals Achieves Enrollment Target For Forodesine CTCL Pivotal Study
Financial Deals Landscape
Mundipharma International Limited, Deals Summary
Mundipharma International Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Mundipharma Enters Into Agreement With Purdue Pharma
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Licensing Agreements
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Asset Transactions
Sosei Group Reacquires Rights To AD923 From Mundipharma
Acquisition
Mundipharma International Acquires Clinical Designs From Abingworth Management
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Mundipharma International Limited, Key Information
Mundipharma International Limited, Key Facts
Mundipharma International Limited – Pipeline by Indication, 2013
Mundipharma International Limited – Pipeline by Stage of Development, 2013
Mundipharma International Limited – Monotherapy Products in Pipeline, 2013
Mundipharma International Limited – Combination Treatment Modalities in Pipeline, 2013
Mundipharma International Limited – Filed, 2013
Mundipharma International Limited – Phase III, 2013
Mundipharma International Limited – Phase II, 2013
Mundipharma International Limited – Pre-Clinical, 2013
Mundipharma International Limited – Pipeline By Route of Administration, 2013
Mundipharma International Limited – Pipeline Products By Mechanism of Action, 2013
Mundipharma International Limited – Recent Pipeline Updates, 2013
Mundipharma International Limited - Dormant Developmental Projects,2013
Mundipharma International Limited, Other Locations
Mundipharma International Limited, Subsidiaries
Mundipharma International Limited, Deals Summary
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Mundipharma Enters Into Agreement With Purdue Pharma
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Sosei Group Reacquires Rights To AD923 From Mundipharma
Mundipharma International Acquires Clinical Designs From Abingworth Management
LIST OF FIGURES
Mundipharma International Limited – Pipeline by Indication, 2013
Mundipharma International Limited – Pipeline by Stage of Development, 2013
Mundipharma International Limited – Monotherapy Products in Pipeline, 2013
Mundipharma International Limited – Combination Treatment Modalities in Pipeline, 2013
Mundipharma International Limited – Pipeline By Route of Administration, 2013
Mundipharma International Limited - Pipeline Products By Mechanism of Action, 2013
